Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

van Noord, J. A.; Schreurs, A. J. M.; Mol, S. J. M.; Mulder, P. G. H.
March 1999
Thorax;Mar1999, p207
Academic Journal
No abstract available.


Related Articles

  • Salmeterol/Fluticasone Propionate. McKeage, Kate; Keam, Susan J. // Drugs;2009, Vol. 69 Issue 13, p1799 

    Salmeterol/fluticasone propionate (Seretide/Advair Diskus® [dry powder inhaler] or Seretide/Advair® inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting b2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with...

  • Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. Bodzenta-Lukaszyk, Anna; Dymek, Andrzej; McAulay, Kirsten; Mansikka, Heikki // BMC Pulmonary Medicine;2011, Vol. 11 Issue 1, p28 

    Background: The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting b2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/ formoterol, flutiform®) in a single aerosol inhaler. This 12-week,...

  • Budesonide/formoterol good value for asthma maintenance in Europe.  // PharmacoEconomics & Outcomes News;11/5/2005, Issue 490, p8 

    The article discusses a study on the cost effectiveness of maintenance therapy with budesonide/formoterol versus dose-titrated salmeterol/fluticasone propionate among patients with moderate-to-severe asthma. Using pooled trial data for Europe, the researchers found that the increased...

  • Salmeterol/Fluticasone Propionate: A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease. Keating, Gillian M.; McCormack, Paul L. // Drugs;2007, Vol. 67 Issue 16, p2383 

    Salmeterol/fluticasone propionate (Seretide®, Advair®, Viani®) administered using a multidose dry powder inhaler (Diskus®, Accuhaler®) is approved for use in the treatment of chronic obstructive pulmonary disease (COPD) in numerous countries. Salmeterol/fluticasone propionate...

  • Salmeterol/fluticasone of value for mild-to-moderate asthma.  // PharmacoEconomics & Outcomes News;7/14/2007, Issue 532, p1 

    The article presents a study on salmeterol/fluticasone for treatment of mild to moderate asthma. According to the research, the most cost effective first-line controller therapy in mild to moderate asthma is salmeterol/fluticasone propionate compared to fluticasone inhaled corticosteroids...

  • Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Bjermer, Leif; Bisgaard, Hans; Bousquet, Jean; Fabbri, Leonardo M; Greening, Andrew P; Haahtela, Tari; Holgate, Stephen T; Picado, Cesar; Menten, Joris; Dass, S Balachandra; Left, Jonathan A; Polos, Peter G // BMJ: British Medical Journal (International Edition);10/18/2003, Vol. 327 Issue 7420, p891 

    Abstract Objectives: To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting: A 52 week, two period, double blind, multicentre trial...

  • Salmeterol/fluticasone propionate.  // Reactions Weekly;12/8/2007, Issue 1181, p33 

    The article describes the case of a 39-year-old woman with asthma and seasonal allergies who developed perioral dermatitis during treatment with inhaled salmeterol/fluticasone propionate. The patient developed a pruritic skin eruption on her chin after two months of treatment with a...

  • Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma. Johansson, G.; McIvor, R.A.; D'Ambrosio, F.P.; Gratziou, C.; James, M.H. // Clinical Drug Investigation;2001, Vol. 21 Issue 9, p633 

    Objective: To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP) combination product (50/100µg twice daily) with budesonide (BUD) at a four-fold higher microgram dose (400µg twice daily) in patients with mild-to-moderate asthma uncontrolled on existing...

  • Inhaled Salmeterol/Fluticasone Propionate Combination. Lyseng-Williamson, Katherine A.; Plosker, Greg L. // PharmacoEconomics;2003, Vol. 21 Issue 13, p951 

    Determines the clinical effectiveness of salmeterol/fluticasone propionate in patients with persistent asthma symptoms in comparative clinical trials. Association of salmeterol/fluticasone propionate with more favorable cost-effectiveness ratios; Improvement with the quality of life.

  • Salmeterol/fluticasone cost effective in asthma in Canada.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p30 

    The article reports on the cost-effectiveness of Salmeterol/fluticasone propionate in treating patients with uncontrolled asthma in Canada.


Read the Article


Sign out of this library

Other Topics